The formulation, termed combinatorial and bioorthogonal nano‐editing complex (ComBiNE), was applied as a therapeutic by incorporation of the drug olaparib and targeting the RAD52 gene, and could substantially suppress tumor growth in vivo in a BRCA‐mutant breast cancer model. This evidence concerns the gene RAD52 and neoplasm.